Spoken Alpha
Forte Biosciences, Inc.
Forte Biosciences develops FB102, a monoclonal antibody in clinical trials targeting CD122 to treat autoimmune diseases including celiac disease, vitiligo, and alopecia areata. The company has completed Phase 1 testing in healthy volunteers and reported positive Phase 1b results in celiac disease, with Phase 2 trials underway.
Forte Biosciences, Inc is a Healthcare company operating in Biotechnology with a $1.63B market cap.
FBRX beat consensus EPS by 0.1% in Q2 FY2026, reported Aug 11, 2026.
Behavioral analysis
Disclosures
Extracted from SEC 10-K filing, 2026-08-30.
Transcripts
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
History
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
Peers
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for FBRX.
$ curl https://api.spokenalpha.com/v1/companies/FBRXFAQ
Spoken Alpha indexes FBRX's earnings call transcripts at https://spokenalpha.com/companies/FBRX. Each call links to attributed speakers and parsed analyst Q&A. Forte Biosciences, Inc.'s own investor relations page is at https://www.fortebiorx.com/investor-relations/news/default.aspx.
Forte Biosciences, Inc. (FBRX) held its most recent earnings call on 2021-05-11, covering fiscal Q1 2021.
Forte Biosciences, Inc. (FBRX) operates in the Healthcare sector (Biotechnology industry).
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q2 FY2026 | 2026-08-11 | $-0.97 | $-1.08 | +10.2% | $0 | — | — | EODHD |
| Q1 FY2026 | 2026-05-10 | $-1.24 | $-1.16 | -6.9% | $0 | — | — | EODHD |
| Q4 FY2025 | 2025-12-30 | $-1.45 | $-1.15 | -26.4% | $0 | — | — | EODHD |
| Q3 FY2025 | 2025-11-13 | $-0.99 | $-1.07 | +7.5% | $0 | — | — | EODHD |
| Q2 FY2025 | 2025-08-13 | $-0.96 | $-1.11 | +13.5% | $0 | — | — | EODHD |
| Q1 FY2025 | 2025-05-14 | $-1.37 | $-0.89 | -53.9% | $0 | — | — | EODHD |
| Q4 FY2024 | 2025-03-27 | $-1.17 | $-0.14 | -100.0% | $38.0K | — | — | EODHD |
| Q3 FY2024 | 2024-11-13 | $-4.54 | $-7.12 | +36.2% | $0 | — | — | EODHD |
| Q2 FY2024 | 2024-08-13 | $-6.75 | $-4.12 | -63.8% | $0 | — | — | EODHD |
| Q1 FY2024 | 2024-05-12 | $-4.00 | $-4.25 | +5.9% | $6.0K | — | — | EODHD |
| Q4 FY2023 | 2024-03-17 | $-0.19 | $-0.28 | +32.1% | $6.0K | — | — | EODHD |
| Q3 FY2023 | 2023-11-12 | $-0.26 | $-0.57 | +54.4% | $0 | — | — | EODHD |
| Q2 FY2023 | 2023-08-13 | $-0.42 | $-0.42 | 0.0% | $0 | — | — | EODHD |
| Q1 FY2023 | 2023-05-14 | $-0.23 | $-0.32 | +27.4% | $0 | — | — | EODHD |
| Q4 FY2022 | 2023-03-30 | $-0.23 | $-0.16 | -43.8% | $0 | — | — | EODHD |
| Q3 FY2022 | 2022-11-13 | $-4.50 | $-3.75 | -20.0% | $0 | — | — | EODHD |
| Q2 FY2022 | 2022-08-14 | $-5.25 | $-4.75 | -10.5% | $0 | — | — | EODHD |
| Q1 FY2022 | 2022-05-15 | $-0.17 | $-0.17 | 0.0% | $0 | — | — | EODHD |
| Q4 FY2021 | 2022-03-30 | $-0.21 | $-0.32 | +34.4% | $0 | — | — | EODHD |
| Q3 FY2021 | 2021-11-07 | $-13.50 | $-9.31 | -45.0% | $0 | — | — | EODHD |
Source: EODHD. FBRX reported actuals as published; sparse fields render as —.